Biosynex SA
PAR:ALBIO
Operating Margin
Biosynex SA
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| FR |
|
Biosynex SA
PAR:ALBIO
|
23.4m EUR |
-36%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
230.3B USD |
17%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
182.6B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
149.8B USD |
19%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
143.5B USD |
22%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.7B USD |
20%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.8B EUR |
14%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48.3B USD |
13%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
43.5B USD |
28%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.3B USD |
29%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
275.5B CNY |
34%
|
Biosynex SA
Glance View
Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Biosynex SA's most recent financial statements, the company has Operating Margin of -35.9%.
You don't have any saved screeners yet